CORCEPT THERAPEUTICS INC - Common Stock (CORT) Institutional Ownership

13F Institutional Holders and Ownership History from Q1 2014 to Q4 2025

Type / Class
Equity / Common Stock
Symbol
CORT on Nasdaq
Shares outstanding
105,863,294
Price per share
$34.80
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
77,185,883
Total reported value
$6,410,521,140
% of total 13F portfolios
0.01%
Share change
-1,985,762
Value change
-$142,243,701
Number of holders
421
Price from insider filings
$34.80
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of CORCEPT THERAPEUTICS INC - Common Stock (CORT) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BlackRock, Inc. 11% -14% $832,430,602 -$130,576,574 11,539,099 -14% BlackRock, Inc. 30 Jun 2025
INGALLS & SNYDER LLC 7.8% $648,748,236 8,173,721 INGALLS & SNYDER LLC 31 Dec 2024
BELANOFF JOSEPH K 6.3% $541,488,729 6,822,335 Joseph K. Belanoff 31 Dec 2024

As of 30 Sep 2025, 421 institutional investors reported holding 77,185,883 shares of CORCEPT THERAPEUTICS INC - Common Stock (CORT). This represents 73% of the company’s total 105,863,294 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of CORCEPT THERAPEUTICS INC - Common Stock (CORT) together control 58% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
BlackRock, Inc. 11% 12,047,830 -3.9% 0.02% $1,001,295,112
VANGUARD GROUP INC 9% 9,537,071 -1.5% 0.01% $792,625,970
INGALLS & SNYDER LLC 7.3% 7,697,984 -0.32% 21% $639,779,000
RENAISSANCE TECHNOLOGIES LLC 5.8% 6,089,347 -2.8% 0.67% $506,085,629
Parallel Advisors, LLC 3.7% 3,871,452 +0.01% 5.9% $321,756,376
STATE STREET CORP 2.8% 2,970,400 +0.09% 0.01% $246,869,944
FMR LLC 2.1% 2,201,938 +62% 0.01% $183,003,047
GEODE CAPITAL MANAGEMENT, LLC 1.8% 1,934,272 +0.97% 0.01% $161,530,218
DIMENSIONAL FUND ADVISORS LP 1.8% 1,892,448 -9.3% 0.03% $157,284,888
AQR CAPITAL MANAGEMENT LLC 1.4% 1,507,209 +547% 0.08% $125,264,121
MORGAN STANLEY 1.1% 1,186,977 -26% 0.01% $98,649,849
Clearbridge Investments, LLC 1.1% 1,161,828 -0.52% 0.07% $96,559,510
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 1% 1,070,281 +31% 0.01% $88,951,054
TD Asset Management Inc 0.9% 956,136 +17% 0.06% $79,464,463
JPMORGAN CHASE & CO 0.8% 849,864 +223% 0% $70,632,217
Epoch Investment Partners, Inc. 0.8% 847,104 +11% 0.39% $70,402,813
Cerity Partners LLC 0.72% 758,426 +1.6% 0.1% $63,032,785
Invesco Ltd. 0.69% 732,583 -29% 0.01% $60,884,974
FIRST TRUST ADVISORS LP 0.68% 720,224 +34% 0.04% $59,857,775
NORTHERN TRUST CORP 0.61% 642,326 -1.5% 0.01% $53,383,715
Bank of New York Mellon Corp 0.57% 601,499 -5.8% 0.01% $49,990,559
D. E. Shaw & Co., Inc. 0.55% 584,098 -13% 0.04% $48,544,385
Boston Trust Walden Corp 0.53% 562,261 -1.7% 0.34% $46,729,511
UBS Group AG 0.52% 549,938 +414% 0.01% $45,705,347
Driehaus Capital Management LLC 0.5% 526,602 +9.4% 0.31% $43,765,892

Institutional Holders of CORCEPT THERAPEUTICS INC - Common Stock (CORT) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 1,055,319 $38,473,021 -$32,543,580 $34.80 30
2025 Q3 77,185,883 $6,410,521,140 -$142,243,701 $83.11 421
2025 Q2 79,064,524 $5,874,843,278 -$175,364,070 $73.40 418
2025 Q1 81,921,809 $9,114,980,974 -$126,808,574 $114.22 407
2024 Q4 84,200,488 $4,242,131,277 -$143,699,519 $50.39 362
2024 Q3 87,143,111 $4,032,380,841 -$44,003,498 $46.28 319
2024 Q2 89,227,745 $2,899,116,548 -$101,789,124 $32.49 285
2024 Q1 92,778,270 $2,336,696,339 +$175,157,731 $25.19 288
2023 Q4 81,445 $2,645,334 +$1,595,222 $32.48 2
2023 Q3 82,166,648 $2,238,695,293 +$50,481,248 $27.24 241
2023 Q2 80,684,528 $1,795,120,981 -$140,191,033 $22.25 221
2023 Q1 87,292,527 $1,890,729,210 +$89,826,334 $21.66 231
2022 Q4 83,369,718 $1,693,541,150 -$55,202,729 $20.31 239
2022 Q3 85,361,834 $2,188,897,546 +$74,760,936 $25.64 218
2022 Q2 83,511,460 $1,960,425,512 +$67,559,694 $23.78 208
2022 Q1 81,073,121 $1,830,167,275 +$18,277,867 $22.52 208
2021 Q4 80,520,494 $1,593,873,243 -$6,668,477 $19.80 196
2021 Q3 80,869,781 $1,591,457,895 +$5,509,288 $19.68 195
2021 Q2 80,507,323 $1,769,405,198 -$29,793,545 $22.00 195
2021 Q1 81,343,088 $1,934,406,564 -$39,945,025 $23.79 205
2020 Q4 81,728,632 $2,137,340,586 -$132,386,334 $26.16 216
2020 Q3 89,200,534 $1,552,149,140 +$5,233,394 $17.40 214
2020 Q2 89,585,112 $1,506,653,948 +$28,369,489 $16.82 214
2020 Q1 85,939,012 $1,021,848,063 -$19,881,410 $11.89 191
2019 Q4 89,063,766 $1,077,729,997 +$45,477,091 $12.10 199
2019 Q3 84,056,622 $1,188,341,878 +$2,453,579 $14.13 186
2019 Q2 85,813,158 $956,795,210 +$2,161,809 $11.15 174
2019 Q1 87,114,270 $1,023,062,430 -$45,364,303 $11.74 198
2018 Q4 90,576,452 $1,209,635,556 +$18,940,822 $13.36 210
2018 Q3 89,601,858 $1,256,022,904 +$21,601,464 $14.02 199
2018 Q2 87,008,613 $1,367,512,744 +$15,651,650 $15.72 207
2018 Q1 86,522,546 $1,423,414,483 -$23,319,484 $16.45 203
2017 Q4 88,616,485 $1,600,522,743 +$258,911,480 $18.06 181
2017 Q3 73,847,277 $1,424,958,805 +$85,438,923 $19.30 186
2017 Q2 69,634,660 $821,926,874 +$108,849,443 $11.80 152
2017 Q1 60,655,544 $664,729,310 +$147,777,504 $10.96 132
2016 Q4 53,330,829 $387,201,104 +$44,065,884 $7.26 137
2016 Q3 47,182,049 $306,732,706 +$9,895,268 $6.50 111
2016 Q2 45,722,770 $249,636,429 +$14,818,537 $5.46 109
2016 Q1 33,862,019 $158,456,671 -$1,015,018 $4.68 95
2015 Q4 34,112,793 $169,885,914 -$117,947 $4.98 95
2015 Q3 34,255,309 $128,827,965 +$5,199,428 $3.76 94
2015 Q2 31,869,411 $191,515,928 +$11,884,570 $6.01 78
2015 Q1 30,334,599 $169,851,880 +$9,774,502 $5.60 60
2014 Q4 28,641,443 $85,896,641 -$1,424,431 $3.00 49
2014 Q3 29,312,101 $78,551,805 -$1,074,861 $2.68 53
2014 Q2 29,699,275 $83,150,770 -$5,487,387 $2.80 60
2014 Q1 30,424,008 $132,580,801 +$11,111,684 $4.36 58